Main description:

The mature T and NK cell lymphomas are rare, comprising approximately 10% of all malignant lymphomas. The incidence of T-cell lymphoma is variable around the world, with a higher incidence compared to B-cell lymphomas in the Asian basin. While the overall incidence of B-cell lymphomas has begun to decline in the United States, the incidence of T-cell lymphomas continues to rise. Over the last decade, a number of novel agents have been developed which target T-cell lymphomas and studies have identified novel genes and pathways associated with lymphomagenesis in T-cells.

This comprehensive volume examines the clinical and biological aspects of the T-cell lymphoproliferative disorders in adults and children. The book includes an overview of both the cutaneous and the systemic T-cell malignancies and addresses the classification of T-cell lymphomas, the clinical features of each subtype, and the relevant molecular and genetic studies. Clinical outcomes and treatment strategies are discussed with an emphasis on the development of novel biological and targeted therapies. An outstanding resource for hematologists and oncologists, this book gathers insights from experts in the field and provides the most up-to-date information on all of the T-cell lymphoma subgroups and current and emerging therapies.

Contents:

Classification of the T-cell lymphomas

Epidemiology, prognosis and outcomes for aggressive T-cell lymphomas -

Molecular pathogenesis of T-cell lymphoma-

HTLV-1 associated T-cell diseases-

The NK/T cell lymphomas-

CD30 positive T-cell lymphomas-

Extranodal T-cell lymphomas

Nodal T-cell lymphomas

The T-cell leukemias

Chemotherapy and Bone Marrow Transplantation

Antibodies and Targeted Therapies

Novel agents for T-cell lymphomas

Immune Therapies in T-cell lymphoma